戻る
Alphamab Oncology (09966.HK)価格
09966.HK 株価推移チャート
ALPHAMAB-B (09966.HK)
Alphamab Oncology
HK$10.2
-0.77%
$-0.08
休場: Jan 16, 16:00:00 HKT
データなしEarnings FAQ
09966.HKの最近の1株当たり利益（EPS）は予想と比較してどうでしたか？
Alphamab Oncology 09966.HKの前四半期の収益はどうでしたか？
Alphamab Oncologyの収益見積もりはいくらですか？
Alphamab Oncologyの収益品質スコアはどれくらいですか？
Alphamab Oncologyはいつ収益を報告しますか？
Alphamab Oncologyの予想収益はいくらですか？
Alphamab Oncologyは収益予想を上回りましたか？
主要データ
前終値
$10.28
始値
$10.28
当日レンジ
$9.87 - $10.4
52週レンジ
$3.05 - $15.75
取引高
1.4M
平均取引高
2.5M
1株当たり利益(TTM)
0.27
配当利回り
--
時価総額
$9.8B
ALPHAMAB-Bとは何ですか？
Alphamab Oncology is an investment holding company. The company is headquartered in Suzhou, Jiangsu and currently employs 484 full-time employees. The company went IPO on 2019-12-12. The Company’s in-house pipeline consists of antibody-drug conjugates (ADCs), monoclonal antibodies and bispecific antibodies in staggered development status in oncology. The Company’s product pipeline includes KN046 (PD-L1/CTLA-4 bispecific antibody), KN026 (HER2/HER2 bispecific antibody), KN035 (SubQ PD-L1), JSKN003 (HER2 biparatopic ADC), JSKN016(HER3/TROP2 bispecific antibody ADC), JSKN033(subcutaneous co-formulation of JSKN003 and KN035), used for indications such as 1L sq NSCLC, 1L HER2+ BC, 1L biliary track cancer, advanced solid tumors, HER2-expressing solid tumors and others.